Skip to main content

Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results.

Publication ,  Journal Article
Reardon, D; Desjardins, A; Vredenburgh, JJ; Gururangan, S; Peters, KB; Norfleet, JA
Published in: J Clin Oncol
May 20, 2009

2046 Background: Significant therapeutic benefit has been observed among recurrent malignant glioma (MG) patients treated with bevacizumab (BV), a neutralizing monoclonal antibody to vascular endothelial growth factor (VEGF) with or without chemotherapy. In this study, we evaluate the efficacy of BV plus etoposide (E), a topoisomerase inhibitor, among recurrent MG patients. METHODS: Recurrent patients with no more than three prior episodes of recurrence are eligible, while those with prior BV treatment or prior intracranial hemorrhage are excluded. The primary outcome measure is 6 month progression-free survival (6-PFS). BV is dosed at 10 mg/kg intravenously every other week. Etoposide is orally administered daily (50 mg/m2) for days 1-21 of each 28-day cycle. RESULTS: Fifty-nine patients (GBM, n = 27; grade 3 MG, n = 32) with a median of 2 prior progressions have enrolled. With a median follow-up of 45 weeks, median overall survival (OS) for GBM and grade 3 MG patients were 46 and 47 weeks, while the 6-PFS is 44% and 40.6%, respectively. The most common toxicities were neutropenia (41%), fatigue (22%), and infection (20%) and were grade 2 in most cases. One patient developed grade 1 intracranial hemorrhage and 1 patient had a grade 4 GI perforation. CONCLUSIONS: Combination of bevacizumab and etoposide is well tolerated in recurrent MG patients and is associated with encouraging anti-tumor benefit. Accrual is complete and an update of further treatment and follow-up will be presented. No significant financial relationships to disclose.

Duke Scholars

Published In

J Clin Oncol

EISSN

1527-7755

Publication Date

May 20, 2009

Volume

27

Issue

15_suppl

Start / End Page

2046

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Peters, K. B., & Norfleet, J. A. (2009). Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J Clin Oncol, 27(15_suppl), 2046.
Reardon, D., A. Desjardins, J. J. Vredenburgh, S. Gururangan, K. B. Peters, and J. A. Norfleet. “Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results.J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2046.
Reardon D, Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Norfleet JA. Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J Clin Oncol. 2009 May 20;27(15_suppl):2046.
Reardon, D., et al. “Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results.J Clin Oncol, vol. 27, no. 15_suppl, May 2009, p. 2046.
Reardon D, Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Norfleet JA. Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J Clin Oncol. 2009 May 20;27(15_suppl):2046.

Published In

J Clin Oncol

EISSN

1527-7755

Publication Date

May 20, 2009

Volume

27

Issue

15_suppl

Start / End Page

2046

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences